This inventor holds 1 USPTO granted patent. Top assignees: Keio University, Regimmune Corporation. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2021
Title: Natsumi Hirata: Innovator in Natural Killer T Cell Activation
Introduction
Natsumi Hirata is a prominent inventor based in Yokohama, Japan. She has made significant contributions to the field of immunology, particularly in the activation of natural killer T cells. Her innovative work has led to the development of a novel compound that has potential applications in pharmaceutical compositions.
Latest Patents
Natsumi Hirata holds 1 patent for her invention titled "Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition." The primary objective of her invention is to provide a new compound or a salt capable of activating natural killer T cells. This invention includes a natural killer T cell activating agent that contains the aforementioned compound or a salt thereof. The compound is represented by a specific formula, and it is designed to enhance the activation of natural killer T cells, which are crucial for immune response.
Career Highlights
Throughout her career, Natsumi Hirata has worked with notable organizations, including Regimmune Corporation and Keio University. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Natsumi has collaborated with esteemed colleagues such as Toshihiko Aiba and Junichiro Kishi. These partnerships have further enriched her research and development efforts in the area of natural killer T cell activation.
Conclusion
Natsumi Hirata's innovative work in the field of immunology highlights her dedication to advancing medical science. Her contributions, particularly in the activation of natural killer T cells, have the potential to lead to significant advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile